Tempest Therapeutics (TPST) Competitors $7.83 +0.07 (+0.90%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$8.04 +0.21 (+2.68%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TPST vs. CCCC, ZNTL, ALEC, TNXP, SLN, COYA, BHST, IMUX, ELUT, and ZURAShould you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include C4 Therapeutics (CCCC), Zentalis Pharmaceuticals (ZNTL), Alector (ALEC), Tonix Pharmaceuticals (TNXP), Silence Therapeutics (SLN), Coya Therapeutics (COYA), BioHarvest Sciences (BHST), Immunic (IMUX), Elutia (ELUT), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry. Tempest Therapeutics vs. C4 Therapeutics Zentalis Pharmaceuticals Alector Tonix Pharmaceuticals Silence Therapeutics Coya Therapeutics BioHarvest Sciences Immunic Elutia Zura Bio Tempest Therapeutics (NASDAQ:TPST) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends. Which has stronger earnings & valuation, TPST or CCCC? Tempest Therapeutics has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTempest TherapeuticsN/AN/A-$29.49M-$19.51-0.40C4 Therapeutics$35.58M3.23-$132.49M-$1.51-1.07 Do institutionals & insiders hold more shares of TPST or CCCC? 22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 4.7% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor TPST or CCCC? Tempest Therapeutics received 75 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 65.38% of users gave Tempest Therapeutics an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformTempest TherapeuticsOutperform Votes10265.38% Underperform Votes5434.62% C4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% Which has more volatility & risk, TPST or CCCC? Tempest Therapeutics has a beta of -2.34, suggesting that its stock price is 334% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Does the media refer more to TPST or CCCC? In the previous week, Tempest Therapeutics had 4 more articles in the media than C4 Therapeutics. MarketBeat recorded 5 mentions for Tempest Therapeutics and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.93 beat Tempest Therapeutics' score of 0.17 indicating that C4 Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tempest Therapeutics Neutral C4 Therapeutics Positive Do analysts rate TPST or CCCC? Tempest Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 283.14%. C4 Therapeutics has a consensus target price of $12.50, indicating a potential upside of 671.60%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than Tempest Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is TPST or CCCC more profitable? Tempest Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat Tempest Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tempest TherapeuticsN/A -187.44% -82.61% C4 Therapeutics -313.35%-42.45%-27.55% SummaryC4 Therapeutics beats Tempest Therapeutics on 12 of the 17 factors compared between the two stocks. Get Tempest Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TPST vs. The Competition Export to ExcelMetricTempest TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.55M$6.74B$5.48B$7.80BDividend YieldN/A3.11%5.42%4.24%P/E Ratio-5.127.2722.3118.46Price / SalesN/A241.32394.17104.18Price / CashN/A65.8538.1834.62Price / Book5.636.356.724.21Net Income-$29.49M$143.17M$3.22B$248.18M7 Day Performance10.13%8.02%6.54%7.25%1 Month Performance-21.99%-1.45%-0.95%0.53%1 Year Performance-82.99%-1.75%17.05%4.89% Tempest Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TPSTTempest Therapeutics2.3796 of 5 stars$7.83+0.9%$30.00+283.1%-83.0%$27.55MN/A-5.1220Gap UpCCCCC4 Therapeutics2.1063 of 5 stars$1.40+12.0%$12.50+792.9%-73.7%$99.39M$35.58M-0.82150Upcoming EarningsZNTLZentalis Pharmaceuticals2.3265 of 5 stars$1.36+5.4%$8.24+506.2%-87.2%$97.66M$67.43M-0.55160Upcoming EarningsNews CoveragePositive NewsALECAlector3.6611 of 5 stars$0.97+5.8%$3.50+259.6%-77.9%$96.45M$100.56M-0.57270Upcoming EarningsTNXPTonix Pharmaceuticals2.4087 of 5 stars$14.96-4.8%$585.00+3,810.4%-96.8%$96.27M$10.09M0.0050Short Interest ↑SLNSilence Therapeutics2.3556 of 5 stars$3.20+1.9%$40.67+1,170.8%-83.8%$95.78M$43.26M-2.04100News CoverageCOYACoya Therapeutics2.0235 of 5 stars$5.71+8.6%$17.00+197.7%-28.3%$95.50M$3.55M-8.786Analyst ForecastHigh Trading VolumeBHSTBioHarvest SciencesN/A$5.81+2.8%$13.00+123.8%N/A$95.43M$25.19M-4.65N/AIMUXImmunic2.3065 of 5 stars$0.99+0.9%$13.20+1,234.5%-8.2%$94.77MN/A-0.8070Gap UpELUTElutia3.2701 of 5 stars$2.30-0.9%$9.00+291.3%-21.6%$93.70M$24.38M-0.88180Short Interest ↑Gap DownZURAZura Bio2.9435 of 5 stars$1.37+11.4%$14.67+970.6%-68.0%$93.67MN/A-2.583Short Interest ↓ Related Companies and Tools Related Companies CCCC Alternatives ZNTL Alternatives ALEC Alternatives TNXP Alternatives SLN Alternatives COYA Alternatives BHST Alternatives IMUX Alternatives ELUT Alternatives ZURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TPST) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tempest Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
